A detailed history of Vanguard Group Inc transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,108,268 shares of RAPT stock, worth $6.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,108,268
Previous 2,492,850 24.69%
Holding current value
$6.22 Million
Previous $22.4 Million 57.65%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.89 - $9.38 $1.78 Million - $5.77 Million
615,418 Added 24.69%
3,108,268 $9.48 Million
Q1 2024

May 10, 2024

BUY
$6.87 - $26.45 $3 Million - $11.5 Million
436,629 Added 21.23%
2,492,850 $22.4 Million
Q4 2023

Feb 14, 2024

BUY
$11.28 - $25.46 $371,292 - $838,041
32,916 Added 1.63%
2,056,221 $51.1 Million
Q3 2023

Nov 14, 2023

BUY
$16.34 - $24.66 $1.25 Million - $1.88 Million
76,356 Added 3.92%
2,023,305 $33.6 Million
Q2 2023

Aug 14, 2023

BUY
$16.06 - $21.61 $5.87 Million - $7.9 Million
365,431 Added 23.11%
1,946,949 $36.4 Million
Q1 2023

May 15, 2023

BUY
$17.19 - $30.8 $1.28 Million - $2.29 Million
74,345 Added 4.93%
1,581,518 $29 Million
Q4 2022

Feb 10, 2023

BUY
$16.28 - $24.6 $3.63 Million - $5.49 Million
223,265 Added 17.39%
1,507,173 $29.8 Million
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $329,799 - $559,336
18,363 Added 1.45%
1,283,908 $30.9 Million
Q2 2022

Aug 12, 2022

BUY
$10.26 - $23.59 $420,660 - $967,190
41,000 Added 3.35%
1,265,545 $23.1 Million
Q1 2022

May 13, 2022

BUY
$17.02 - $40.22 $309,644 - $731,722
18,193 Added 1.51%
1,224,545 $26.9 Million
Q4 2021

Feb 14, 2022

BUY
$29.5 - $39.5 $3.76 Million - $5.03 Million
127,466 Added 11.81%
1,206,352 $44.3 Million
Q3 2021

Nov 12, 2021

BUY
$29.86 - $39.47 $4.93 Million - $6.51 Million
164,970 Added 18.05%
1,078,886 $33.5 Million
Q2 2021

Aug 13, 2021

BUY
$17.99 - $40.02 $16.4 Million - $36.6 Million
913,916 New
913,916 $29.1 Million

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $59.3M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.